Glenmark Pharmaceuticals has received final USFDA approval for Ezetimibe and Simvastatin tablets, used for treating high levels of cholesterol in the blood. The approved product is a generic version of MSD International’s Vytorin tablets.
The product will be manufactured in the strengths of 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg.
According to market estimates, Vytorin tablets’ market achieved annual sales of approximately $92.4 million for the 12-month period ended April 2019.
Company Profile : Glenmark Pharma Ltd